STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Biotage (STO:BIOTA) has made the decision to transfer instrument production from its Charlottesville, VA factory in the U.S. to a contract manufacturer. Through this decision, the company takes yet another step to increase efficiency in business activities. Biotage expects this measure to enable substantial cost savings, a reduction in tied-up capital and increased flexibility.
